ResMed Inc. stock holds above support as fiscal 2026 growth and cautious 2027 outlook shape sentiment
Published on 09/06/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. (ISIN US7611521078) stock is quoted at 240.10 USD as of August 31, 2026, according to market data from Yahoo Finance, while the 52-week range spans from 180.27 USD to 284.87 USD, putting the current level clearly below the recent high but well above the low.
Fiscal 2026 figures underpin the valuation
The latest available fundamentals show that ResMed delivered revenue of 5.65 billion USD on a trailing twelve-month basis, with a net income attributable to common shareholders of 1.52 billion USD, according to Yahoo Finance, which corresponds to a profit margin of 26.95% in fiscal 2026.
Quarterly dynamics are important for investors: for Q3 fiscal 2026, ResMed reported revenue of 1.43 billion USD and earnings of 398.73 million USD, implying a quarterly profit margin of 27.86% and confirming that margins remained slightly above the full-year average in that period, based on data compiled by Yahoo Finance.
For shareholders, earnings per share are a key metric: ResMed’s diluted EPS on a trailing twelve-month basis stands at 10.43 USD, while adjusted EPS in Q4 fiscal 2026 came in at 2.95 USD versus an estimate of 2.89 USD, meaning the company beat the consensus by 0.06 USD per share, according to the same earnings overview.
Guidance for fiscal 2027 and analyst view
The stock’s recent behavior is shaped not only by delivered results but also by guidance. According to commentary summarized in the Yahoo Finance overview, ResMed is facing a softer fiscal 2027 outlook due in part to suspended ventilator sales, which has weighed on sentiment even after strong Q4 figures with revenue up 9% year over year and adjusted EPS rising 16% in that quarter.
Visible analyst targets illustrate the current consensus corridor: the latest price target from an analyst at Rothschild and Co is 230 USD with a neutral rating as of August 19, 2026, while the average one-year target estimate compiled in the same overview stands at 245.50 USD, with a low of 175.00 USD and a high of 320.00 USD.
From a valuation perspective, ResMed trades at a trailing price-earnings ratio of 23.02 based on the 10.43 USD EPS figure, and the market capitalization is approximately 34.64 billion USD on an intraday basis as reported in the Yahoo Finance statistics, placing the group firmly among larger medical instruments and supplies peers.
ResMed Inc. fundamentals and stock data
For more detailed figures and historical data on ResMed Inc., including previous quarters and longer-term performance, the Ad-Hoc News topic page bundles current news and key metrics on the stock.
Sleep and breathing solutions as growth driver
ResMed’s business is centered on digital health and cloud-connected medical devices for sleep and breathing disorders, especially obstructive sleep apnea. According to the company profile on Yahoo Finance, ResMed operates in two segments: Sleep and Breathing Health and Residential Care Software, combining physical devices with software platforms.
On the device side, ResMed offers products such as ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow and snoring, along with NightOwl, a disposable, cloud-connected diagnostic device that measures sleep apnea severity based on peripheral arterial tone, actigraphy and oximetry. These systems are complemented by EasyCare Tx for sleep labs.
Connectivity is a major competitive factor: the AirView cloud system enables remote monitoring and adjustment of therapy devices, while the myAir application provides patients with support, education and troubleshooting tools for higher compliance. This combination of hardware and software has helped ResMed to maintain double-digit revenue growth in recent years, although fiscal 2027 guidance suggests a more moderate pace.
ResMed AirMini as a representative product
One representative ResMed product for retail investors to understand the company’s offering is the AirMini AutoSet Travel CPAP Machine. According to the product description on the e-commerce specialist CPAP.com, the AirMini AutoSet is a compact continuous positive airway pressure device designed for travel, using ResMed’s AutoSet algorithms to automatically adjust pressure based on detected breathing events.
The product carries a manufacturer warranty of two years and is positioned as a premium travel solution that complements larger home CPAP devices. For ResMed, such portable devices expand the addressable market among frequent travelers and improve patient adherence, supporting the Sleep and Breathing Health segment’s contribution to overall revenue.
Stock level and investor perspective
ResMed Inc. stock closed at 240.10 USD on the New York Stock Exchange on August 31, 2026, according to Yahoo Finance, compared with a 52-week high of 284.87 USD and a 52-week low of 180.27 USD, which means the shares currently trade around 15.7% below the yearly high but roughly 33.2% above the yearly low.
ResMed Inc. stock key data
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: RMD
- Trading venue: NYSE
- Price (as of August 31, 2026): 240.10 USD
- Market capitalization: 34.64 billion USD (as of August 31, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: S&P 500
